CNC — Claude Opus 4.8

I'll research CNC (Centene Corporation) before writing the preview. Let me gather recent filings, transcripts, and news.Let me read the most recent quarter's transcript and release, plus check for recent news.Let me get recent stock price action and any recent news/press releases heading into the print.Let me pull recent healthcare-sector news and CNC-specific context to round out the setup.# Centene (CNC) — Q2 2026 Earnings Preview

Reports before market open, Tuesday July 28, 2026 (results ~6:00 a.m. ET; call 8:30 a.m. ET)

The Setup: A Redemption Story in Full Swing

Centene enters this print as one of the biggest turnaround trades in managed care over the past 12 months. The stock cratered from ~$57 to ~$34 on July 2, 2025 when the company pulled its 2025 guidance over Marketplace risk-adjustment shortfalls, and bottomed near $25–27 in late July/early August 2025. It has since more than doubled, closing at $64.10 on July 27, 2026 — up ~53% year-to-date in 2026 and up ~135% from the 2025 trough. The 52-week range is roughly $25.5 to $68.7.

The rally accelerated after a strong Q1 2026 print (reported April 28): shares jumped from ~$43.50 pre-print to ~$54 within two days. Expectations have reset sharply higher, which raises the bar for tomorrow. After a beat-and-raise Q1, the market is now looking for confirmation that the margin-recovery narrative is durable — and, critically, for the Marketplace risk-adjustment "true-up" that management explicitly teed up for this quarter.

The Single Most Important Thing to Watch: The June Wakely Data & Marketplace Risk Adjustment

This is the swing factor for the print and the likely source of any guidance move.

On the Q1 call, management said their greater-than-$3.40 FY26 adjusted EPS guidance does NOT reflect the full potential risk-adjustment offset they believe they're owed on higher-acuity Silver members. They embedded a conservative ~3% Marketplace pretax margin vs. an original ~4% target, and flipped their year-end risk-transfer assumption from a payable to a slight receivable.
CFO Drew Asher and CEO Sarah London both flagged the June Wakely report (claims + risk-score data across the market) as the key catalyst to refine that assumption and update the full-year view. This is the quarter that data arrives.
The bull case: if the June data corroborates the higher-acuity thesis, CNC books a larger receivable, Marketplace margin moves back toward (or above) 4%, and guidance gets raised again. Management said the range of outcomes "wraps around" the original 4% margin "and higher than that at the top end."
The bear case: if June data doesn't confirm the acuity/risk-score story (echoes of the 2025 blowup), the Marketplace recovery stalls. Given how much the stock has re-rated on this thesis, the risk is asymmetric — a disappointment here would hit harder than a beat helps.

Watch for: the updated year-end risk-transfer position (receivable vs. payable), the revised Marketplace pretax margin, and whether the FY26 EPS floor moves above $3.40.

Watch the EPS Cadence — Don't Panic at the Q2 Step-Down

A likely source of confusion tomorrow: Q1 adjusted EPS was $3.37, yet full-year guidance is only "greater than $3.40." That is not a mistake — it reflects heavy back-half seasonality plus deliberate conservatism.

Management guided to this cadence explicitly: - Q1: strong (done — $3.37) - Q2: step down from Q1, but still profitable - Q3: around breakeven - Q4: a loss (driven by commercial/Marketplace HBR seasonality, PDP sloping, and heavy Q4 SG&A for open enrollment)

So a large sequential EPS decline in Q2 is expected and baked in. The more important reads are the segment HBRs vs. plan and any guidance revision, not the headline Q2 number in isolation. The ">$3.40" floor is best read as a conservative floor that embeds unrecognized Marketplace upside.

Segment-by-Segment Scorecard (What "Good" Looks Like)

Medicaid (~$23.6B Q1 premium; 12.4M members) - Q1 HBR was 93.1%, down 50 bps YoY — a third straight quarter of margin progress, helped by lighter flu/weather but with genuine underlying trend-management gains. - Framework: net trend ~mid-4%, composite rate yield ~4.5%, with FY HBR guide implying ~93.7%. London said she'd be "disappointed" to only hit 93.7% and hinted at 15–20 bps of outperformance. - Watch: confirmation that behavioral health / home health / high-cost-drug trend is decelerating as claimed; commentary on rate adequacy and state receptiveness; and early signals on work requirements (Nebraska began 7/1) feeding into 2027 rate/acuity discussions.

Medicare (MA + PDP) (~$10.3B Q1 premium) - Q1 segment HBR 84.9%, beating on both MA and PDP. Reiterated a path to MA breakeven in 2027; encouraged that final 2027 MA rates improved vs. the advance notice. - PDP (8.8M members, largest standalone Part D player): saw slightly lower specialty-drug trend than feared; expects the 2027 direct subsidy to rise "quite a bit" again given the risk-model lag on non-low-income/IRA dynamics. - Watch: Medicare segment HBR sloping (should ramp steeply through the year on PDP mix — this is normal, not a red flag), and any read-through to 2027 MA bids.

Commercial / Marketplace (Q1 Commercial HBR 75.3%) - Membership dropped to 3.58M (from 5.6M a year ago) on the enhanced-APTC-driven market contraction; management expects to end 2026 "a little over 3 million." - Q1 HBR ran slightly hot on higher Silver-tier utilization — the crux of the risk-adjustment debate above.

Balance Sheet & Capital

CNC used proceeds from selling $1.0B of 2025 Part D risk-share receivables to repurchase $1.0B of 2027 senior notes, cutting debt-to-cap to 43.2% (from 46.5% at YE25).
Q1 operating cash flow was a strong $4.4B; ~$437M cash available for general corporate use; DCP at 48 days.
Watch: further receivable monetization, debt maturities in Dec-2027 and summer-2028 (management plans to refinance ~1 year out), and any signal of resumed buybacks — a potential incremental catalyst as cash generation normalizes.

Key Risks & Overhangs Into the Print

eAPTC expiration — the enhanced premium tax credits lapsed, driving the Marketplace membership cliff. The bigger 2027 question (subsidy renewal, shortened open-enrollment period, program-integrity rules) hangs over the stock; watch for any policy commentary.
Medicaid work requirements (OBBBA/OB3) — implementation risk to acuity/risk pools in 2027–2028, partly offset by CMS guidance allowing midyear rate/retro adjustments.
Elevated absolute trend — behavioral health, home health, high-cost/specialty drugs and PDP specialty trend all remain "historically high," even if decelerating.
Sentiment/valuation risk — after doubling, CNC needs continued execution; a soft Marketplace read or failure to raise guidance could unwind a crowded recovery trade.
Credibility — a year after the guidance-pull, management is being graded on whether the new visibility framework (the Wakely early-data process they helped create) actually holds up.

Bottom Line

The bar is high after a beat-and-raise Q1 and a doubling in the stock, and the print will likely live or die on the June Wakely data and whether the Marketplace risk-adjustment receivable materializes. A confirming data set that lets CNC book a fuller receivable and nudge the ">$3.40" floor higher — alongside continued Medicaid HBR progress and MA/PDP outperformance — would validate the turnaround. Conversely, any wobble in the Marketplace acuity thesis, or a failure to raise, could pressure a stock that has already priced in a lot of good news. Expect a Q2 EPS step-down by design; focus on segment HBRs vs. plan, the Marketplace margin/risk-transfer update, and the tone on 2027 (eAPTC, Medicaid work requirements, MA breakeven).

Note: This preview is based on Centene's own disclosures (Q1 2026 release and earnings call) and market data; it is research/analysis, not investment advice.